The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Parkinson’s Disease Therapeutics Pipeline Program, 2025Developing Novel Lysosome-based Translational Biomarkers and Ion-Channel Agonists as Therapeutics for Parkinson’s Disease
Study Rationale: Lysosomal dysfunction impairs cells’ ability to recycle their damaged components and is a primary contributor to the progression of Parkinson's disease (PD). TMEM175, a novel ion...
-
iPSC Phenotyping Environmental Exposure Program, 2024Phenotyping Environmental Exposure to Long-lasting Chemicals, Nanoplastics and Pesticides in iPSC Dopaminergic Neurons and Glia
Study Rationale: Of high priority is a need to understand the impact of pesticides, emerging long-lived chemicals, Per- and Polyfluoroalkyl Substances, and nanoplastics on neurons and glial cells and...
-
Spring 2022 RFA: Cellular Phenotyping in Human iPSCS from the PPMI Cohort, 2022Metabolic Phenotyping in PD Dopaminergic Neurons and Neuronal-glial Co-cultures Using High-throughput Single-cell Metabolomics and Lipidomics
Study Rationale: Recent studies have discovered metabolism to be altered in Parkinson’s disease with cells changing their bioenergetic pathways and accumulating metabolite markers. Every cell in our...
-
Parkinson’s Disease Therapeutics Pipeline Program, 2024IND-enabling Studies of a Molecule that Enhances Mitophagy as Disease-modifying Therapy for Parkinson's Disease
Study Rationale: Studies show that Parkinson's disease (PD) is frequently associated with damage to mitochondria, structures that provide cells with the energy they need to function. In particular, a...
-
2021 RFA: PIPETTE 4R Tau and Alpha-Synuclein PET Tracer Development, 2024SUPPLEMENT: Rescreening of the MJFF Compound Library to Identify Molecules that Can be Used to Monitor Alpha-synuclein
Study Rationale: Alpha-synuclein is a key protein involved in the pathology of Parkinson’s disease (PD). We recently confirmed that two compounds developed under the MJFF Alpha-synuclein Imaging...
-
ASAP CRN Competitive Renewal Opportunity, 2024Mapping the Modulatory Landscape Governing Dopamine-acetylcholine Signaling and its Dysregulation in Parkinson’s Disease
Study Rationale: In people with Parkinson's disease (PD), nerve cells that make and release the chemical dopamine start to die. This loss affects the striatum, a brain region that normally receives...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.